According to the Shanghai Pharmaceutical announcement, amisulpride tablets from Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd., a subsidiary of the company, were successfully included in the “National Medical Insurance Catalogue” through national health insurance negotiations. The agreement is valid from January 1, 2026 to December 31, 2027. Amisulpride tablets are an improved dosage form of amisulpride tablets marketed by Sanofi in France in 1986 to treat schizophrenia in adults. In October 2025, with the approval of the State Drug Administration, Shangyao Zhongxi became the marketing license holder for amisulpride tablets. As of the date of this announcement, no other companies in China have listed amisulpride tablets. According to the IQVIA database, hospital purchases of amisulpride oral preparations in 2024 were 168 million yuan.

According to the Shanghai Pharmaceutical announcement, amisulpride tablets from Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd., a subsidiary of the company, were successfully included in the “National Medical Insurance Catalogue” through national health insurance negotiations. The agreement is valid from January 1, 2026 to December 31, 2027. Amisulpride tablets are an improved dosage form of amisulpride tablets marketed by Sanofi in France in 1986 to treat schizophrenia in adults. In October 2025, with the approval of the State Drug Administration, Shangyao Zhongxi became the marketing license holder for amisulpride tablets. As of the date of this announcement, no other companies in China have listed amisulpride tablets. According to the IQVIA database, hospital purchases of amisulpride oral preparations in 2024 were 168 million yuan.